Anagliptin Ameliorates Albuminuria and Urinary Liver-type Fatty Acid-binding Protein Excretion in Patients with Type 2 Diabetes with Nephropathy in a Glucose-lowering-independent Manner

Overview

Journal BMJ Open Diabetes Res Care

Specialty Endocrinology

Date 2017 Aug 2

PMID 28761658

Citations 8

Authors

Munehiro Kitada

Shin-Ichi Tsuda

Kazunori Konishi

Ai Takeda-Watanabe

Mizue Fujii

Keizo Kanasaki

Makoto Nishizawa

Atsushi Nakagawa

Daisuke Koya

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy.

Methods: Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who were switched to anagliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors were analyzed regarding primary and secondary endpoints. The primary endpoint was change in hemoglobin A1c (HbA1c) during treatment with anagliptin. Additionally, we evaluated changes in lipid data (low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglyceride), blood pressure (BP), urinary albumin to creatinine ratio (UACR), liver-type fatty acid-binding protein to creatinine ratio (ULFABP) and renal function (estimated glomerular filtration rate and serum cystatin C) as secondary endpoints.

Results: After switching to anagliptin from other DPP-4 inhibitors, the levels of HbA1c in the 20 participants showed no significant change, 7.5%±1.2% at 24 weeks compared with 7.3%±0.9% at baseline. The levels of the log10-transformed UACR were significantly reduced from 1.95±0.51 mg/g creatinine (Cr) at baseline to 1.76±0.53 mg/g Cr at 24 weeks after anagliptin treatment (p<0.01). The percentage change in the UACR (Δ%UACR) from baseline to 24 weeks was also significantly lower by -10.6% (p<0.001). Lipid data, systolic BP and renal function were not changed during anagliptin treatment. Additionally, ULFABP in eight participants, who had ≥5 µg/g Cr at baseline, was significantly decreased from baseline (8.5±2.8 µg/g Cr) to 24 weeks (3.1±1.7 µg/g Cr, p<0.01) after anagliptin treatment, and the percentage change in the ULFABP during anagliptin treatment was -58.1% (p<0.001).

Conclusions: Anagliptin induced no significant change in HbA1c, lipid data, systolic BP and renal function. However, anagliptin reduced the UACR and ULFABP, although without a corresponding change in HbA1c, indicating direct action of anagliptin on renoprotection in patients with type 2 diabetic nephropathy.

Citing Articles

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.

Elbarbary N, Ismail E, El-Hamamsy M, Ibrahim M, Elkholy A Diabetologia. 2024; 67(12):2637-2649.

PMID: 39271520 PMC: 11604790. DOI: 10.1007/s00125-024-06265-7.

Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.

Hirowatari K, Kawano N Int Urol Nephrol. 2023; 55(8):2111-2118.

PMID: 36840803 DOI: 10.1007/s11255-023-03532-1.

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.

Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M Diabetes Metab Syndr Obes. 2022; 15:685-694.

PMID: 35264863 PMC: 8901417. DOI: 10.2147/DMSO.S350518.

Renoprotective Effects of DPP-4 Inhibitors.

Kawanami D, Takashi Y, Takahashi H, Motonaga R, Tanabe M Antioxidants (Basel). 2021; 10(2).

PMID: 33562528 PMC: 7915260. DOI: 10.3390/antiox10020246.

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).

Liakos C, Papadopoulos D, Sanidas E, Markou M, Hatziagelaki E, Grassos C Am J Cardiovasc Drugs. 2020; 21(2):123-137.

PMID: 32780214 DOI: 10.1007/s40256-020-00423-z.

References

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

Mori H, Okada Y, Arao T, Tanaka Y . Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014; 5(3):313-9. PMC: 4020336. DOI: 10.1111/jdi.12142. View

Goto A, Arah O, Goto M, Terauchi Y, Noda M . Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347:f4533. DOI: 10.1136/bmj.f4533. View

Ervinna N, Mita T, Yasunari E, Azuma K, Rica Tanaka , Fujimura S . Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology. 2013; 154(3):1260-70. DOI: 10.1210/en.2012-1855. View

Adler A, Stevens R, Manley S, Bilous R, Cull C, Holman R . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2002; 63(1):225-32. DOI: 10.1046/j.1523-1755.2003.00712.x. View

Tanaka Y, Kume S, Chin-Kanasaki M, Araki H, Araki S, Ugi S . Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury. Biochem Biophys Res Commun. 2016; 470(3):539-545. DOI: 10.1016/j.bbrc.2016.01.109. View

Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M . Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007; 56(6):1727-30. DOI: 10.2337/db06-1646. View

Shi S, Kanasaki K, Koya D . Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochem Biophys Res Commun. 2016; 471(1):184-90. DOI: 10.1016/j.bbrc.2016.01.154. View

Nakashima S, Matsui T, Takeuchi M, Yamagishi S . Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res. 2014; 46(10):717-21. DOI: 10.1055/s-0034-1371892. View

10.

Watanabe Y, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R . Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. J Enzyme Inhib Med Chem. 2015; 30(6):981-8. DOI: 10.3109/14756366.2014.1002402. View

11.

Hattori S . Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011; 58(1):69-73. DOI: 10.1507/endocrj.k10e-382. View

12.

Chen X, He Z, Zhou Z, Yang T, Zhang X, Yang Y . Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015; 42(10):999-1024. DOI: 10.1111/1440-1681.12455. View

13.

Marques C, Mega C, Goncalves A, Rodrigues-Santos P, Teixeira-Lemos E, Teixeira F . Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm. 2014; 2014:538737. PMC: 4000968. DOI: 10.1155/2014/538737. View

14.

Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N . Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun. 2013; 443(3):828-33. DOI: 10.1016/j.bbrc.2013.12.049. View

15.

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View

16.

Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-93. DOI: 10.1056/NEJMoa021778. View

17.

Shinjo T, Nakatsu Y, Iwashita M, Sano T, Sakoda H, Ishihara H . DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. Am J Physiol Endocrinol Metab. 2015; 309(3):E214-23. DOI: 10.1152/ajpendo.00553.2014. View

18.

Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S . A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013; 434(2):191-6. DOI: 10.1016/j.bbrc.2013.03.010. View

19.

Araki S, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S . Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care. 2012; 36(5):1248-53. PMC: 3631864. DOI: 10.2337/dc12-1298. View

20.

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View